HLS Free Cash Flow Per Share vs Book Value Per Share Analysis
HLS Stock | CAD 3.65 0.15 4.29% |
HLS Therapeutics financial indicator trend analysis is much more than just examining HLS Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether HLS Therapeutics is a good investment. Please check the relationship between HLS Therapeutics Free Cash Flow Per Share and its Book Value Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Free Cash Flow Per Share vs Book Value Per Share
Free Cash Flow Per Share vs Book Value Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of HLS Therapeutics Free Cash Flow Per Share account and Book Value Per Share. At this time, the significance of the direction appears to have no relationship.
The correlation between HLS Therapeutics' Free Cash Flow Per Share and Book Value Per Share is 0.06. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of HLS Therapeutics, assuming nothing else is changed. The correlation between historical values of HLS Therapeutics' Free Cash Flow Per Share and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of HLS Therapeutics are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Free Cash Flow Per Share i.e., HLS Therapeutics' Free Cash Flow Per Share and Book Value Per Share go up and down completely randomly.
Correlation Coefficient | 0.06 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most indicators from HLS Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into HLS Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, HLS Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 13th of December 2024, Sales General And Administrative To Revenue is likely to grow to 0.18, though Tax Provision is likely to grow to (258.4 K).
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 60.0M | 61.5M | 63.1M | 56.1M | Interest Expense | 7.0M | 7.3M | 8.7M | 9.2M |
HLS Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
HLS Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
HLS Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 319.7M | 303.9M | 275.9M | 241.7M | 209.1M | 114.0M | |
Short Long Term Debt Total | 93.1M | 107.1M | 97.6M | 97.3M | 87.6M | 51.5M | |
Other Current Liab | 21.8M | 6.2M | 901K | 6.0M | 1.7M | 1.6M | |
Total Current Liabilities | 47.1M | 35.6M | 27.7M | 31.2M | 26.7M | 18.0M | |
Total Stockholder Equity | 178.2M | 169.2M | 160.7M | 125.3M | 97.7M | 64.7M | |
Property Plant And Equipment Net | 1.3M | 1.4M | 1.6M | 1.1M | 965K | 916.8K | |
Current Deferred Revenue | 5.8M | 5.1M | 4.8M | 5.7M | 6.6M | 6.9M | |
Net Debt | 46.0M | 86.5M | 76.4M | 76.6M | 65.7M | 69.0M | |
Retained Earnings | (81.5M) | (101.6M) | (119.9M) | (148.4M) | (175.5M) | (166.7M) | |
Accounts Payable | 13.5M | 14.2M | 9.3M | 11.6M | 14.1M | 8.9M | |
Non Current Assets Total | 256.6M | 258.0M | 232.2M | 197.3M | 165.0M | 173.2M | |
Non Currrent Assets Other | 2.2M | 2.0M | 714K | 668K | 619K | 588.1K | |
Other Assets | 3.2M | 3.2M | 1.4M | 1.1M | 1.3M | 861.2K | |
Cash And Short Term Investments | 47.1M | 20.6M | 21.2M | 20.7M | 22.0M | 16.9M | |
Net Receivables | 11.9M | 12.5M | 11.5M | 11.2M | 10.7M | 11.6M | |
Common Stock Shares Outstanding | 29.4M | 31.7M | 32.2M | 32.4M | 32.3M | 23.1M | |
Liabilities And Stockholders Equity | 319.7M | 303.9M | 275.9M | 241.7M | 209.1M | 114.0M | |
Non Current Liabilities Total | 94.3M | 99.0M | 87.5M | 85.1M | 84.7M | 88.9M | |
Inventory | 2.1M | 10.6M | 8.9M | 8.9M | 9.5M | 10.0M | |
Other Current Assets | 2.1M | 2.2M | 2.1M | 3.6M | 1.9M | 1.6M | |
Other Stockholder Equity | 11.5M | 11.4M | 11.7M | 13.8M | 13.9M | 16.7M | |
Total Liab | 141.5M | 134.7M | 115.2M | 116.3M | 111.4M | 116.9M | |
Property Plant And Equipment Gross | 1.3M | 1.4M | 3.5M | 3.3M | 3.1M | 2.9M | |
Total Current Assets | 63.1M | 45.9M | 43.8M | 44.4M | 44.1M | 32.9M | |
Accumulated Other Comprehensive Income | (537K) | 2.0M | 3.0M | (5.3M) | (2.8M) | (2.7M) | |
Short Term Debt | 6.0M | 10.1M | 12.6M | 13.6M | 5.2M | 4.7M | |
Intangible Assets | 252.1M | 253.4M | 229.2M | 195.0M | 162.3M | 173.4M | |
Cash | 47.1M | 20.6M | 21.2M | 20.7M | 22.0M | 18.1M | |
Common Stock Total Equity | 192.7M | 210.4M | 248.7M | 257.4M | 296.0M | 310.8M | |
Common Stock | 248.7M | 257.4M | 265.9M | 265.2M | 262.1M | 169.5M | |
Other Liab | 15.7M | 5.1M | 2.5M | 1.4M | 1.2M | 1.2M | |
Net Tangible Assets | (73.9M) | (84.2M) | (68.4M) | (69.7M) | (80.2M) | (84.2M) | |
Long Term Debt | 86.6M | 96.2M | 84.1M | 83.3M | 82.0M | 86.2M | |
Capital Surpluse | 11.5M | 11.4M | 11.7M | 13.8M | 15.9M | 10.3M | |
Property Plant Equipment | 1.3M | 1.4M | 1.6M | 1.1M | 1.3M | 928.3K | |
Long Term Debt Total | 87.1M | 97.0M | 85.0M | 83.8M | 96.3M | 91.3M | |
Non Current Liabilities Other | 10.5M | 2.6M | 1.9M | 817K | 1.8M | 1.7M | |
Cash And Equivalents | 47.1M | 20.6M | 21.2M | 20.7M | 18.7M | 20.9M |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
Balance Sheet is a snapshot of the financial position of HLS Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. HLS Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of HLS Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which HLS currently owns. An asset can also be divided into two categories, current and non-current.